Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson’s disease trial

Background Dopamine transporter single-photon emission computed tomography (DaT-SPECT) can quantify the functional integrity of the dopaminergic nerve terminals and has been suggested as an imaging modality to verify the clinical diagnosis of Parkinson's disease (PD). Depending on the stage of...

Full description

Saved in:
Bibliographic Details
Published inBMC neurology Vol. 21; no. 1; pp. 1 - 10
Main Authors Hutchison, R. Matthew, Evans, Karleyton C., Fox, Tara, Yang, Minhua, Barakos, Jerome, Bedell, Barry J., Cedarbaum, Jesse M., Brys, Miroslaw, Siderowf, Andrew, Lang, Anthony E.
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 23.11.2021
BioMed Central
BMC
Subjects
Basal ganglia
Biological markers
Biomarker
Biomarkers
Brain diseases
Carrier proteins
Central nervous system diseases
Clinical medicine
Clinical trials
Computed tomography
CT imaging
Diagnosis
Diagnostic imaging
Dopamine
Dopamine receptors
Dopamine transporter
Drug dosages
Drug therapy
FDA approval
Health aspects
Methods
Monoclonal antibodies
Movement disorders
Nerve endings
Neurodegenerative diseases
Parkinson's disease
Regulatory approval
Single photon emission computed tomography
SPECT
SWEDD
Synuclein
Testing
Thyroid gland
Tomography
Tremor (Muscular contraction)
Work stations
United States
United States > US
Online AccessGet full text

Cover

Abstract Background Dopamine transporter single-photon emission computed tomography (DaT-SPECT) can quantify the functional integrity of the dopaminergic nerve terminals and has been suggested as an imaging modality to verify the clinical diagnosis of Parkinson's disease (PD). Depending on the stage of progression, approximately 5-15% of participants clinically diagnosed with idiopathic PD have been observed in previous studies to have normal DaT-SPECT patterns. However, the utility of DaT-SPECT in enhancing early PD participant selection in a global, multicenter clinical trial of a potentially disease-modifying therapy is not well understood. Methods The SPARK clinical trial was a phase 2 trial of cinpanemab, a monoclonal antibody against alpha-synuclein, in participants with early PD. DaT-SPECT was performed at screening to select participants with DaT-SPECT patterns consistent with degenerative parkinsonism. Acquisition was harmonised across 82 sites. Images were reconstructed and qualitatively read at a central laboratory by blinded neuroradiologists for inclusion prior to automated quantitative analysis. Results In total, 482 unique participants were screened between January 2018 and May 2019; 3.8% (15/398) of imaged participants were excluded owing to negative DaT-SPECT findings (i.e., scans without evidence of dopaminergic deficit [SWEDD]). Conclusion A smaller proportion of SPARK participants were excluded owing to SWEDD status upon DaT-SPECT screening than has been reported in prior studies. Further research is needed to understand the reasons for the low SWEDD rate in this study and whether these results are generalisable to future studies. If supported, the radiation risks, imaging costs, and operational burden of DaT-SPECT for enrichment may be mitigated by clinical assessment and other study design aspects. Trial registration ClinicalTrials.gov identifier: NCT03318523. Date submitted: October 19, 2017. First Posted: October 24, 2017. Keywords: Biomarker, Dopamine transporter, Parkinson's disease, SPECT, SWEDD
AbstractList Background Dopamine transporter single-photon emission computed tomography (DaT-SPECT) can quantify the functional integrity of the dopaminergic nerve terminals and has been suggested as an imaging modality to verify the clinical diagnosis of Parkinson's disease (PD). Depending on the stage of progression, approximately 5-15% of participants clinically diagnosed with idiopathic PD have been observed in previous studies to have normal DaT-SPECT patterns. However, the utility of DaT-SPECT in enhancing early PD participant selection in a global, multicenter clinical trial of a potentially disease-modifying therapy is not well understood. Methods The SPARK clinical trial was a phase 2 trial of cinpanemab, a monoclonal antibody against alpha-synuclein, in participants with early PD. DaT-SPECT was performed at screening to select participants with DaT-SPECT patterns consistent with degenerative parkinsonism. Acquisition was harmonised across 82 sites. Images were reconstructed and qualitatively read at a central laboratory by blinded neuroradiologists for inclusion prior to automated quantitative analysis. Results In total, 482 unique participants were screened between January 2018 and May 2019; 3.8% (15/398) of imaged participants were excluded owing to negative DaT-SPECT findings (i.e., scans without evidence of dopaminergic deficit [SWEDD]). Conclusion A smaller proportion of SPARK participants were excluded owing to SWEDD status upon DaT-SPECT screening than has been reported in prior studies. Further research is needed to understand the reasons for the low SWEDD rate in this study and whether these results are generalisable to future studies. If supported, the radiation risks, imaging costs, and operational burden of DaT-SPECT for enrichment may be mitigated by clinical assessment and other study design aspects. Trial registration ClinicalTrials.gov identifier: NCT03318523. Date submitted: October 19, 2017. First Posted: October 24, 2017. Keywords: Biomarker, Dopamine transporter, Parkinson's disease, SPECT, SWEDD
Dopamine transporter single-photon emission computed tomography (DaT-SPECT) can quantify the functional integrity of the dopaminergic nerve terminals and has been suggested as an imaging modality to verify the clinical diagnosis of Parkinson's disease (PD). Depending on the stage of progression, approximately 5-15% of participants clinically diagnosed with idiopathic PD have been observed in previous studies to have normal DaT-SPECT patterns. However, the utility of DaT-SPECT in enhancing early PD participant selection in a global, multicenter clinical trial of a potentially disease-modifying therapy is not well understood. The SPARK clinical trial was a phase 2 trial of cinpanemab, a monoclonal antibody against alpha-synuclein, in participants with early PD. DaT-SPECT was performed at screening to select participants with DaT-SPECT patterns consistent with degenerative parkinsonism. Acquisition was harmonised across 82 sites. Images were reconstructed and qualitatively read at a central laboratory by blinded neuroradiologists for inclusion prior to automated quantitative analysis. In total, 482 unique participants were screened between January 2018 and May 2019; 3.8% (15/398) of imaged participants were excluded owing to negative DaT-SPECT findings (i.e., scans without evidence of dopaminergic deficit [SWEDD]). A smaller proportion of SPARK participants were excluded owing to SWEDD status upon DaT-SPECT screening than has been reported in prior studies. Further research is needed to understand the reasons for the low SWEDD rate in this study and whether these results are generalisable to future studies. If supported, the radiation risks, imaging costs, and operational burden of DaT-SPECT for enrichment may be mitigated by clinical assessment and other study design aspects.
Background Dopamine transporter single-photon emission computed tomography (DaT-SPECT) can quantify the functional integrity of the dopaminergic nerve terminals and has been suggested as an imaging modality to verify the clinical diagnosis of Parkinson’s disease (PD). Depending on the stage of progression, approximately 5–15% of participants clinically diagnosed with idiopathic PD have been observed in previous studies to have normal DaT-SPECT patterns. However, the utility of DaT-SPECT in enhancing early PD participant selection in a global, multicenter clinical trial of a potentially disease-modifying therapy is not well understood. Methods The SPARK clinical trial was a phase 2 trial of cinpanemab, a monoclonal antibody against alpha-synuclein, in participants with early PD. DaT-SPECT was performed at screening to select participants with DaT-SPECT patterns consistent with degenerative parkinsonism. Acquisition was harmonised across 82 sites. Images were reconstructed and qualitatively read at a central laboratory by blinded neuroradiologists for inclusion prior to automated quantitative analysis. Results In total, 482 unique participants were screened between January 2018 and May 2019; 3.8% (15/398) of imaged participants were excluded owing to negative DaT-SPECT findings (i.e., scans without evidence of dopaminergic deficit [SWEDD]). Conclusion A smaller proportion of SPARK participants were excluded owing to SWEDD status upon DaT-SPECT screening than has been reported in prior studies. Further research is needed to understand the reasons for the low SWEDD rate in this study and whether these results are generalisable to future studies. If supported, the radiation risks, imaging costs, and operational burden of DaT-SPECT for enrichment may be mitigated by clinical assessment and other study design aspects. Trial registration ClinicalTrials.gov identifier: NCT03318523. Date submitted: October 19, 2017. First Posted: October 24, 2017.
Dopamine transporter single-photon emission computed tomography (DaT-SPECT) can quantify the functional integrity of the dopaminergic nerve terminals and has been suggested as an imaging modality to verify the clinical diagnosis of Parkinson's disease (PD). Depending on the stage of progression, approximately 5-15% of participants clinically diagnosed with idiopathic PD have been observed in previous studies to have normal DaT-SPECT patterns. However, the utility of DaT-SPECT in enhancing early PD participant selection in a global, multicenter clinical trial of a potentially disease-modifying therapy is not well understood.BACKGROUNDDopamine transporter single-photon emission computed tomography (DaT-SPECT) can quantify the functional integrity of the dopaminergic nerve terminals and has been suggested as an imaging modality to verify the clinical diagnosis of Parkinson's disease (PD). Depending on the stage of progression, approximately 5-15% of participants clinically diagnosed with idiopathic PD have been observed in previous studies to have normal DaT-SPECT patterns. However, the utility of DaT-SPECT in enhancing early PD participant selection in a global, multicenter clinical trial of a potentially disease-modifying therapy is not well understood.The SPARK clinical trial was a phase 2 trial of cinpanemab, a monoclonal antibody against alpha-synuclein, in participants with early PD. DaT-SPECT was performed at screening to select participants with DaT-SPECT patterns consistent with degenerative parkinsonism. Acquisition was harmonised across 82 sites. Images were reconstructed and qualitatively read at a central laboratory by blinded neuroradiologists for inclusion prior to automated quantitative analysis.METHODSThe SPARK clinical trial was a phase 2 trial of cinpanemab, a monoclonal antibody against alpha-synuclein, in participants with early PD. DaT-SPECT was performed at screening to select participants with DaT-SPECT patterns consistent with degenerative parkinsonism. Acquisition was harmonised across 82 sites. Images were reconstructed and qualitatively read at a central laboratory by blinded neuroradiologists for inclusion prior to automated quantitative analysis.In total, 482 unique participants were screened between January 2018 and May 2019; 3.8% (15/398) of imaged participants were excluded owing to negative DaT-SPECT findings (i.e., scans without evidence of dopaminergic deficit [SWEDD]).RESULTSIn total, 482 unique participants were screened between January 2018 and May 2019; 3.8% (15/398) of imaged participants were excluded owing to negative DaT-SPECT findings (i.e., scans without evidence of dopaminergic deficit [SWEDD]).A smaller proportion of SPARK participants were excluded owing to SWEDD status upon DaT-SPECT screening than has been reported in prior studies. Further research is needed to understand the reasons for the low SWEDD rate in this study and whether these results are generalisable to future studies. If supported, the radiation risks, imaging costs, and operational burden of DaT-SPECT for enrichment may be mitigated by clinical assessment and other study design aspects.CONCLUSIONA smaller proportion of SPARK participants were excluded owing to SWEDD status upon DaT-SPECT screening than has been reported in prior studies. Further research is needed to understand the reasons for the low SWEDD rate in this study and whether these results are generalisable to future studies. If supported, the radiation risks, imaging costs, and operational burden of DaT-SPECT for enrichment may be mitigated by clinical assessment and other study design aspects.ClinicalTrials.gov identifier: NCT03318523 . Date submitted: October 19, 2017. First Posted: October 24, 2017.TRIAL REGISTRATIONClinicalTrials.gov identifier: NCT03318523 . Date submitted: October 19, 2017. First Posted: October 24, 2017.
Abstract Background Dopamine transporter single-photon emission computed tomography (DaT-SPECT) can quantify the functional integrity of the dopaminergic nerve terminals and has been suggested as an imaging modality to verify the clinical diagnosis of Parkinson’s disease (PD). Depending on the stage of progression, approximately 5–15% of participants clinically diagnosed with idiopathic PD have been observed in previous studies to have normal DaT-SPECT patterns. However, the utility of DaT-SPECT in enhancing early PD participant selection in a global, multicenter clinical trial of a potentially disease-modifying therapy is not well understood. Methods The SPARK clinical trial was a phase 2 trial of cinpanemab, a monoclonal antibody against alpha-synuclein, in participants with early PD. DaT-SPECT was performed at screening to select participants with DaT-SPECT patterns consistent with degenerative parkinsonism. Acquisition was harmonised across 82 sites. Images were reconstructed and qualitatively read at a central laboratory by blinded neuroradiologists for inclusion prior to automated quantitative analysis. Results In total, 482 unique participants were screened between January 2018 and May 2019; 3.8% (15/398) of imaged participants were excluded owing to negative DaT-SPECT findings (i.e., scans without evidence of dopaminergic deficit [SWEDD]). Conclusion A smaller proportion of SPARK participants were excluded owing to SWEDD status upon DaT-SPECT screening than has been reported in prior studies. Further research is needed to understand the reasons for the low SWEDD rate in this study and whether these results are generalisable to future studies. If supported, the radiation risks, imaging costs, and operational burden of DaT-SPECT for enrichment may be mitigated by clinical assessment and other study design aspects. Trial registration ClinicalTrials.gov identifier: NCT03318523 . Date submitted: October 19, 2017. First Posted: October 24, 2017.
ArticleNumber 459
Audience Academic
Author Evans, Karleyton C.
Barakos, Jerome
Lang, Anthony E.
Hutchison, R. Matthew
Cedarbaum, Jesse M.
Bedell, Barry J.
Siderowf, Andrew
Fox, Tara
Yang, Minhua
Brys, Miroslaw
Author_xml – sequence: 1
  givenname: R. Matthew
  surname: Hutchison
  fullname: Hutchison, R. Matthew
– sequence: 2
  givenname: Karleyton C.
  surname: Evans
  fullname: Evans, Karleyton C.
– sequence: 3
  givenname: Tara
  surname: Fox
  fullname: Fox, Tara
– sequence: 4
  givenname: Minhua
  surname: Yang
  fullname: Yang, Minhua
– sequence: 5
  givenname: Jerome
  surname: Barakos
  fullname: Barakos, Jerome
– sequence: 6
  givenname: Barry J.
  surname: Bedell
  fullname: Bedell, Barry J.
– sequence: 7
  givenname: Jesse M.
  surname: Cedarbaum
  fullname: Cedarbaum, Jesse M.
– sequence: 8
  givenname: Miroslaw
  surname: Brys
  fullname: Brys, Miroslaw
– sequence: 9
  givenname: Andrew
  surname: Siderowf
  fullname: Siderowf, Andrew
– sequence: 10
  givenname: Anthony E.
  surname: Lang
  fullname: Lang, Anthony E.
BookMark eNp9Uk1rFTEUHaRiP_QPuAq4cTM1mWSSOxuhlKqFgi50He4kmffyOpM8k3kFd_4N_56_xExfRV8RCSHh3nNOci7ntDoKMbiqesnoOWMg32TWAPCaNqxsoWgNT6oTJhSrG67U0V_34-o05w2lTIFgz6pjLoAJkOqkur26w3GHsw8rYuMWJx8cmROGvI1pdon4CVdLEzPBQFxI3qwnF2bS-zhhul0ggSDZrjE70pBPpeZDjuHn9x-ZWJ_dUp-Tx_F59XTAMbsXD-dZ9eXd1efLD_XNx_fXlxc3tZFUzjWHHlFYpwzv2w4kkwKl6eTAjO2N6GzHaWs5UKsYDLQdHDJFsW2oUANVjJ9V13tdG3Gjt6lYSN90RK_vCzGtNKbZm9FpKsoEhexb6UBQo3oL3Nihl65TauhU0Xq719ru-slZU5wnHA9EDzvBr_Uq3mmQtANoi8DrB4EUv-5cnvXks3HjiMHFXdaNpKzrWuBQoK8eQTdxl0IZVUExxjnvGvYHtcJiwIchlnfNIqovJEihoGlkQZ3_A1WWdZM3JUeDL_UDAuwJJsWckxu08XPJRVxs-VEzqpfQ6X3odAmdvg-dXv7dPKL-Hs9_SL8A7yHaag
CitedBy_id crossref_primary_10_1056_NEJMoa2203395
crossref_primary_10_1186_s13550_024_01121_6
crossref_primary_10_1007_s00415_024_12770_x
crossref_primary_10_1186_s40035_022_00286_1
crossref_primary_10_2967_jnumed_121_263197
crossref_primary_10_1021_acsomega_4c09114
crossref_primary_10_1097_MNM_0000000000001968
crossref_primary_10_37349_ent_2023_00048
crossref_primary_10_1212_WNL_0000000000209137
crossref_primary_10_1016_j_heliyon_2024_e27437
crossref_primary_10_1093_brain_awad265
crossref_primary_10_1111_psyg_70006
Cites_doi 10.1002/mds.21505
10.1186/1471-2377-7-27
10.1002/1531-8257(200007)15:4<692::aid-mds1014>3.0.co;2-v
10.1212/wnl.46.1.231
10.1136/jnnp-2014-310256
10.1111/cts.12492
10.1001/jama.2014.3654
10.1016/j.parkreldis.2014.11.007
10.1007/s11307-015-0889-6
10.1186/s13550-015-0087-1
10.1002/ana.410380407
10.1136/jnnp.2006.110122
10.1212/01.wnl.0000277648.63931.c0
10.1056/NEJMoa033447
10.1186/s41824-018-0028-0
10.1002/mds.10580
10.1001/archneur.59.4.580
10.1212/wnl.52.6.1206
10.1212/WNL.0000000000000424
10.1016/j.parkreldis.2016.07.002
10.1136/jnnp.51.6.745
10.3233/JPD-191648
10.1002/mds.24000
10.1109/tns.1978.4329385
10.1212/01.wnl.0000191390.20564.8e
10.1212/WNL.0b013e318248e520
10.1097/WAD.0000000000000144
10.1002/ana.10609
10.1111/ene.12458
10.1136/jnnp.2009.193391
10.1093/brain/awf080
10.1002/acn3.644
10.1016/j.nbd.2018.10.016
10.1016/j.jns.2017.11.039
10.1212/WNL.0000000000000641
10.1136/jnnp.55.3.181
10.1007/s00259-012-2304-8
10.1001/jama.287.13.1653
10.1002/mds.10482
10.1212/WNL.0000000000002876
10.1097/RLU.0000000000001477
10.1002/mds.22108
ContentType Journal Article
Copyright COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021. The Author(s).
The Author(s) 2021
Copyright_xml – notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021. The Author(s).
– notice: The Author(s) 2021
DBID AAYXX
CITATION
3V.
7TK
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12883-021-02470-8
DatabaseName CrossRef
ProQuest Central (Corporate)
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

Publicly Available Content Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2377
EndPage 10
ExternalDocumentID oai_doaj_org_article_0488346b56e840c7bd83cdfb6e977f97
PMC8609885
A686478226
10_1186_s12883_021_02470_8
GeographicLocations United States
United States--US
GeographicLocations_xml – name: United States
– name: United States--US
GrantInformation_xml – fundername: ;
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABIVO
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IGS
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
PMFND
3V.
7TK
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c606t-38baa4de7c3b5986164a6c96f1cdbc49d9305d380d718f05fea170a52047f0713
IEDL.DBID 7X7
ISSN 1471-2377
IngestDate Wed Aug 27 01:25:45 EDT 2025
Thu Aug 21 18:12:43 EDT 2025
Fri Jul 11 06:04:04 EDT 2025
Fri Jul 25 02:47:11 EDT 2025
Tue Jun 17 21:28:37 EDT 2025
Tue Jun 10 20:45:36 EDT 2025
Thu Apr 24 23:01:45 EDT 2025
Tue Jul 01 00:37:35 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c606t-38baa4de7c3b5986164a6c96f1cdbc49d9305d380d718f05fea170a52047f0713
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
OpenAccessLink https://www.proquest.com/docview/2611333921?pq-origsite=%requestingapplication%
PMID 34814867
PQID 2611333921
PQPubID 44772
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_0488346b56e840c7bd83cdfb6e977f97
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8609885
proquest_miscellaneous_2601995838
proquest_journals_2611333921
gale_infotracmisc_A686478226
gale_infotracacademiconefile_A686478226
crossref_citationtrail_10_1186_s12883_021_02470_8
crossref_primary_10_1186_s12883_021_02470_8
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-11-23
PublicationDateYYYYMMDD 2021-11-23
PublicationDate_xml – month: 11
  year: 2021
  text: 2021-11-23
  day: 23
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle BMC neurology
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References WR Gibb (2470_CR21) 1988; 51
JP Seibyl (2470_CR15) 1995; 38
F Nobili (2470_CR42) 2013; 40
SR Suwijn (2470_CR17) 2015; 5
K Marek (2470_CR10) 2014; 82
K Marek (2470_CR27) 2018; 5
Parkinson Study Group (2470_CR7) 2002; 287
N Nicastro (2470_CR33) 2018; 385
LD Perju-Dumbrava (2470_CR35) 2012; 27
R de la Fuente-Fernández (2470_CR31) 2012; 78
K Marek (2470_CR45) 2006; 66
KA Jellinger (2470_CR4) 2016; 87
D Stephenson (2470_CR25) 2019; 9
S Fahn (2470_CR8) 2004; 351
N Nicastro (2470_CR39) 2016; 18
F Ba (2470_CR36) 2015; 21
C Scherfler (2470_CR5) 2007; 22
AL Whone (2470_CR6) 2003; 54
L-T Chang (2470_CR41) 1978; 25
Z Walker (2470_CR34) 2007; 78
RC Dodel (2470_CR11) 2003; 18
NP Bajaj (2470_CR19) 2010; 81
A Weihofen (2470_CR37) 2019; 124
DJ Conrado (2470_CR23) 2018; 11
N Nicastro (2470_CR38) 2016; 31
2470_CR16
J Sevigny (2470_CR46) 2016; 30
KL Marek (2470_CR9) 2003; 60
European Medicines Agency (2470_CR30) 2018
AJ Hughes (2470_CR1) 2002; 125
R de la Fuente-Fernández (2470_CR32) 2014; 21
M Ichise (2470_CR14) 1999; 52
AJ Hughes (2470_CR20) 1992; 55
European Medicines Agency (2470_CR28) 2000
AM Vlaar (2470_CR18) 2007; 7
N Nicastro (2470_CR40) 2017; 42
KJ Nichols (2470_CR43) 2018; 2
BS Connolly (2470_CR24) 2014; 311
R Erro (2470_CR22) 2016; 87
VL Marshall (2470_CR2) 2009; 24
US Food and Drug Administration (2470_CR29) 2011
CH Adler (2470_CR3) 2014; 83
KL Marek (2470_CR12) 1996; 46
Parkinson Study Group PRECEPT Investigators (2470_CR26) 2007; 69
MJ Ribeiro (2470_CR13) 2002; 59
HT Benamer (2470_CR44) 2003; 18
References_xml – volume: 22
  start-page: 1229
  year: 2007
  ident: 2470_CR5
  publication-title: Mov Disord
  doi: 10.1002/mds.21505
– volume-title: Qualification opinion on dopamine transporter imaging as an enrichment biomarker for Parkinson’s disease clinical trials in patients with early parkinsonian symptoms
  year: 2018
  ident: 2470_CR30
– volume: 7
  start-page: 27
  year: 2007
  ident: 2470_CR18
  publication-title: BMC Neurol
  doi: 10.1186/1471-2377-7-27
– ident: 2470_CR16
  doi: 10.1002/1531-8257(200007)15:4<692::aid-mds1014>3.0.co;2-v
– volume: 46
  start-page: 231
  year: 1996
  ident: 2470_CR12
  publication-title: Neurology.
  doi: 10.1212/wnl.46.1.231
– volume: 87
  start-page: 319
  year: 2016
  ident: 2470_CR22
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp-2014-310256
– volume: 11
  start-page: 63
  year: 2018
  ident: 2470_CR23
  publication-title: Clin Transl Sci
  doi: 10.1111/cts.12492
– volume: 311
  start-page: 1670
  year: 2014
  ident: 2470_CR24
  publication-title: JAMA.
  doi: 10.1001/jama.2014.3654
– volume: 21
  start-page: 87
  year: 2015
  ident: 2470_CR36
  publication-title: Parkinsonism Relat Disord
  doi: 10.1016/j.parkreldis.2014.11.007
– volume: 18
  start-page: 302
  year: 2016
  ident: 2470_CR39
  publication-title: Mol Imaging Biol
  doi: 10.1007/s11307-015-0889-6
– volume: 5
  start-page: 12
  year: 2015
  ident: 2470_CR17
  publication-title: EJNMMI Res
  doi: 10.1186/s13550-015-0087-1
– volume-title: DaTscan (ioflupane I 123 injection) [prescribing information]
  year: 2011
  ident: 2470_CR29
– volume: 38
  start-page: 589
  year: 1995
  ident: 2470_CR15
  publication-title: Ann Neurol
  doi: 10.1002/ana.410380407
– volume: 78
  start-page: 1176
  year: 2007
  ident: 2470_CR34
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp.2006.110122
– volume: 69
  start-page: 1480
  year: 2007
  ident: 2470_CR26
  publication-title: Neurology.
  doi: 10.1212/01.wnl.0000277648.63931.c0
– volume: 351
  start-page: 2498
  year: 2004
  ident: 2470_CR8
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa033447
– volume: 2
  start-page: 10
  year: 2018
  ident: 2470_CR43
  publication-title: Eur J Hybrid Imaging
  doi: 10.1186/s41824-018-0028-0
– volume: 18
  start-page: S52
  issue: Suppl 7
  year: 2003
  ident: 2470_CR11
  publication-title: Mov Disord
  doi: 10.1002/mds.10580
– volume: 59
  start-page: 580
  year: 2002
  ident: 2470_CR13
  publication-title: Arch Neurol
  doi: 10.1001/archneur.59.4.580
– volume-title: DaTSCAN: ioflupane (123l) [prescribing information]
  year: 2000
  ident: 2470_CR28
– volume: 52
  start-page: 1206
  year: 1999
  ident: 2470_CR14
  publication-title: Neurology.
  doi: 10.1212/wnl.52.6.1206
– volume: 82
  start-page: 1791
  year: 2014
  ident: 2470_CR10
  publication-title: Neurology.
  doi: 10.1212/WNL.0000000000000424
– volume: 31
  start-page: 53
  year: 2016
  ident: 2470_CR38
  publication-title: Parkinsonism Relat Disord
  doi: 10.1016/j.parkreldis.2016.07.002
– volume: 51
  start-page: 745
  year: 1988
  ident: 2470_CR21
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp.51.6.745
– volume: 9
  start-page: 553
  year: 2019
  ident: 2470_CR25
  publication-title: J Parkinsons Dis
  doi: 10.3233/JPD-191648
– volume: 27
  start-page: 65
  year: 2012
  ident: 2470_CR35
  publication-title: Mov Disord
  doi: 10.1002/mds.24000
– volume: 25
  start-page: 638
  year: 1978
  ident: 2470_CR41
  publication-title: IEEE Trans NuclSci
  doi: 10.1109/tns.1978.4329385
– volume: 66
  start-page: A112
  year: 2006
  ident: 2470_CR45
  publication-title: Neurology.
  doi: 10.1212/01.wnl.0000191390.20564.8e
– volume: 78
  start-page: 696
  year: 2012
  ident: 2470_CR31
  publication-title: Neurology.
  doi: 10.1212/WNL.0b013e318248e520
– volume: 30
  start-page: 1
  year: 2016
  ident: 2470_CR46
  publication-title: Alzheimer Dis Assoc Disord
  doi: 10.1097/WAD.0000000000000144
– volume: 60
  start-page: A293
  year: 2003
  ident: 2470_CR9
  publication-title: Neurology.
– volume: 54
  start-page: 93
  year: 2003
  ident: 2470_CR6
  publication-title: Ann Neurol
  doi: 10.1002/ana.10609
– volume: 21
  start-page: 1351
  year: 2014
  ident: 2470_CR32
  publication-title: Eur J Neurol
  doi: 10.1111/ene.12458
– volume: 81
  start-page: 1223
  year: 2010
  ident: 2470_CR19
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp.2009.193391
– volume: 125
  start-page: 861
  year: 2002
  ident: 2470_CR1
  publication-title: Brain.
  doi: 10.1093/brain/awf080
– volume: 5
  start-page: 1460
  year: 2018
  ident: 2470_CR27
  publication-title: Ann Clin Transl Neurol
  doi: 10.1002/acn3.644
– volume: 124
  start-page: 276
  year: 2019
  ident: 2470_CR37
  publication-title: Neurobiol Dis
  doi: 10.1016/j.nbd.2018.10.016
– volume: 385
  start-page: 17
  year: 2018
  ident: 2470_CR33
  publication-title: J Neurol Sci
  doi: 10.1016/j.jns.2017.11.039
– volume: 83
  start-page: 406
  year: 2014
  ident: 2470_CR3
  publication-title: Neurology.
  doi: 10.1212/WNL.0000000000000641
– volume: 55
  start-page: 181
  year: 1992
  ident: 2470_CR20
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp.55.3.181
– volume: 40
  start-page: 565
  year: 2013
  ident: 2470_CR42
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-012-2304-8
– volume: 287
  start-page: 1653
  year: 2002
  ident: 2470_CR7
  publication-title: JAMA.
  doi: 10.1001/jama.287.13.1653
– volume: 18
  start-page: 977
  year: 2003
  ident: 2470_CR44
  publication-title: Mov Disord
  doi: 10.1002/mds.10482
– volume: 87
  start-page: 237
  year: 2016
  ident: 2470_CR4
  publication-title: Neurology.
  doi: 10.1212/WNL.0000000000002876
– volume: 42
  start-page: e96
  year: 2017
  ident: 2470_CR40
  publication-title: Clin Nucl Med
  doi: 10.1097/RLU.0000000000001477
– volume: 24
  start-page: 500
  year: 2009
  ident: 2470_CR2
  publication-title: Mov Disord
  doi: 10.1002/mds.22108
SSID ssj0017841
Score 2.377336
Snippet Background Dopamine transporter single-photon emission computed tomography (DaT-SPECT) can quantify the functional integrity of the dopaminergic nerve...
Dopamine transporter single-photon emission computed tomography (DaT-SPECT) can quantify the functional integrity of the dopaminergic nerve terminals and has...
Abstract Background Dopamine transporter single-photon emission computed tomography (DaT-SPECT) can quantify the functional integrity of the dopaminergic nerve...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1
SubjectTerms Basal ganglia
Biological markers
Biomarker
Biomarkers
Brain diseases
Carrier proteins
Central nervous system diseases
Clinical medicine
Clinical trials
Computed tomography
CT imaging
Diagnosis
Diagnostic imaging
Dopamine
Dopamine receptors
Dopamine transporter
Drug dosages
Drug therapy
FDA approval
Health aspects
Methods
Monoclonal antibodies
Movement disorders
Nerve endings
Neurodegenerative diseases
Parkinson's disease
Regulatory approval
Single photon emission computed tomography
SPECT
SWEDD
Synuclein
Testing
Thyroid gland
Tomography
Tremor (Muscular contraction)
Work stations
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LaxRBEG4kB_EiPnE0SguCB2kyvf0-RkkIQjwZyK3p17iLZhKym7t_w7_nL7Gqp3fJKOjF63QNTHdVbdW3XfUVIW-E4oZDJsFUyRIAShQsBBfZEKIrIUYT6mzA00_65Ex-PFfnt0Z9YU3YRA88HdwBWpiQOipdAIskE7MVKQ9RF8hcBlf7yCHmbcFUuz_A27Rti4zVB2uOQ3UZliNATDI9s7MwVNn6__xN_r1O8lbgOX5A7reMkR5OX_qQ3CnjI3L3tN2JPyZfjxph9_iFZoDAF_CUbnac5dd0dVEnEdGwpmGkYC-rtMT_BCm23mN1DoiMNNCrJUQ0uqDYCF17wn5-_7Gm7QaH1vEeT8jZ8dHnDyesjVBgCZDJhgkbQ5C5mCQiMrEDOAo6OT3wlGOSLjvw9yxsnyFGDb0aSuCmD2rRSzMggH1K9sbLsTwjtFjtFODFlIuTWUCqFqQanAwJkr6QTUf49kR9avziOObim684w2o_acGDFnzVgrcdebd752pi1_ir9HtU1E4SmbHrA7AX3-zF_8teOvIW1ezRf-HzUmhtCLBJZMLyh9pi-y1kpR3Zn0mC36X58tZQfPP7tQc8CqAfck7ekde7ZXwTa9nGcnmDMj32xVsBGzIzA5vtbL4yrpaV-9vq3lmrnv-Po3hB7i3QJThnC7FP9jbXN-UlpFib-Kp60y9PtyQe
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LbxMxELZKkRAXxFMECjISEge0sI7fB4QKalUhhRORerP82iZquylJKsGNv8Hf45cw4-wGFqpe12NlvTPjmS_2fEPISy6ZZpBJVDInAQAl8Mp7G6rGB5t9CNqX3oCTz-poKj4dy-Md0rc76j7g6kpoh_2kpsuzN9--fn8PDv-uOLxRb1cMW-ZWeNkAIo6uK3OD3ITIpNFRJ-LPqQKesfWFM1fOGwSnwuH__0797-3Jv8LR4V1yp8sj6f5G8ffITm7vk1uT7qT8ATk96Gi82xOaABifw1O63jKZL-n8vPQnon5FfUvBiuZxhv8UUizIxzs7INJSTy9mEOfomGJ5dKkU-_Xj54p25zq0NP14SKaHB18-HlVdY4UqAl5ZV9wE70XKOvKA_OwAmbyKVjUsphCFTRZ2gcRNnSByNbVssme69nJcC90grH1EdttFmx8Tmo2yElBkTNmKxCGB80I2VvgIqaBPekRY_0Vd7FjHsfnFmSvowyi30YIDLbiiBWdG5PV2zsWGc-Na6Q-oqK0k8mWXB4vlievcz-E-xYUKUmVAtFGHZHhMTVAZ8t_Gwmu-QjU7tDN4vei74gRYJPJjuX1lsCgXctUR2RtIgjfG4XBvKK43ZgcolXEOmSgbkRfbYZyJN9zavLhEmRqr5Q2HBemBgQ1WNhxp57PCCG5UbY2RT67_8afk9hiNnbFqzPfI7np5mZ9BSrUOz4uf_AaKUB7I
  priority: 102
  providerName: Scholars Portal
Title Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson’s disease trial
URI https://www.proquest.com/docview/2611333921
https://www.proquest.com/docview/2601995838
https://pubmed.ncbi.nlm.nih.gov/PMC8609885
https://doaj.org/article/0488346b56e840c7bd83cdfb6e977f97
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LixNBEG50F8SL-MToGloQPEizM5mefpxkI1kWIYssLgQvTb9mE3QnMZO9-zf8e_4Sqzqd6CjsZQ7TNcz0VFVXfd31IORNVZeyBE-C1TFwACiuYtZqxxrrdLTOSZt6A07Pxdkl_zirZ3nDrcthlbs1MS3UYelxj_wYPH2AU2DNy_er7wy7RuHpam6hcZccYukyDOmSsz3gKvFMbZcoo8RxV2JrXYZBCWCZZMFUzxilmv3_r8z_Rkv-ZX5OH5IH2W-kJ1tGPyJ3YvuY3Jvmk_En5Oskl-1ur2gAIHwNd-lmX7l8TRfXqR8RtR21LQWpWfg57gxSTMDHGB0gaamlqznYNTqimA6dMsN-_fjZ0XyOQ1OTj6fk8nTy-cMZy40UmAd8smGVctbyEKWvHNZjB4hkhdeiKX1wnuugQetDpYoAlqop6ibaUha2HhVcNghjn5GDdtnG54RGJXQNqNGHqHmowGGzvG40tx5cPxvkgJS7P2p8rjKOzS6-mYQ2lDBbLhjggklcMGpA3u2fWW1rbNxKPUZG7SmxPna6sVxfmaxuBteligtXiwgI1ksXVOVD40QEf7fR8Jlvkc0GtRg-z9ucjACTxHpY5kQoTMIF33RAjnqUoH2-P7wTFJO1vzN_ZHVAXu-H8UmMaGvj8gZpCsyOVxVMSPYErDez_ki7mKcK4EoUWqn6xe0vf0nuj1DYy5KNqiNysFnfxFfgQm3cMOnJkByOJ-efLoZpIwKuU67gejH-8hugrCAN
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3LbtNAFB2VVAI2iKcIFBgkEAtk1fbY45kFQi2kSmkTIdRK3Q3zchNBnZCkQuz4DX6Cj-JLuNcZGwxSd916xonH93l8X4Q8Y3lSJOBJRLl3GQAUwyKtpYlKbaTXxhS6ng04GvPhcfbuJD_ZID-bWhhMq2x0Yq2o3cziN_Jt8PQBToE1T17Pv0Q4NQqjq80IjTVbHPhvXwGyLV_tvwX6Pk_TvcHRm2EUpgpEFpz1VcSE0TpzvrDMYHNywAuaW8nLxDpjM-kkiIBjInagtss4L71OiljnaZwVJWI6-N0rZDNjAGV6ZHN3MH7_oY1bYBSvKc0RfHuZ4DDfCNMgwBYWcSQ65q-eEvC_Lfg3P_Mvg7d3k9wInirdWbPWLbLhq9vk6ijE4u-QT4PQKLw6pQ6g9xlcpau2V_qCTs_qCUhUL6muKPDp1E7wWyTFkn_MCoItFdV0PgFLSlOKBdh1Ldqv7z-WNESOaD1W5C45vpSXfI_0qlnl7xPqBZc54FTrvMwcAxdRZ3kpM23B2dSu6JOkeaPKhr7mOF7js6rxjeBqTQUFVFA1FZTok5ftPfN1V48Ld-8iodqd2JG7vjBbnKog4Ao1Icu4ybkHzGwL4wSzrjTcg4ddSnjMF0hmhXoDHs_qUP4Ah8QOXGqHCyz7BW-4T7Y6O0HebXe5YRQV9M1S_ZGOPnnaLuOdmENX-dk57omxHl8wOFDRYbDOybor1XRS9xwXPJZC5A8u_vMn5NrwaHSoDvfHBw_J9RQZP0milG2R3mpx7h-BA7cyj4PUUPLxsgX1NztTWTY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluating+dopamine+transporter+imaging+as+an+enrichment+biomarker+in+a+phase+2+Parkinson%E2%80%99s+disease+trial&rft.jtitle=BMC+neurology&rft.au=Hutchison%2C+R+Matthew&rft.au=Evans%2C+Karleyton+C&rft.au=Fox%2C+Tara&rft.au=Yang%2C+Minhua&rft.date=2021-11-23&rft.pub=BioMed+Central&rft.eissn=1471-2377&rft.volume=21&rft.spage=1&rft_id=info:doi/10.1186%2Fs12883-021-02470-8
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2377&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2377&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2377&client=summon